GB201108272D0 - Methods relating to HCMV infected cells - Google Patents
Methods relating to HCMV infected cellsInfo
- Publication number
- GB201108272D0 GB201108272D0 GB201108272A GB201108272A GB201108272D0 GB 201108272 D0 GB201108272 D0 GB 201108272D0 GB 201108272 A GB201108272 A GB 201108272A GB 201108272 A GB201108272 A GB 201108272A GB 201108272 D0 GB201108272 D0 GB 201108272D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- infected cells
- hcmv
- methods relating
- hcmv infected
- mrp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
This invention relates to the identification and/or elimination of Human Cytomegalovirus (HCMV) infected cells from mammalian cell populations by determining the expression of multidrug resistance-associated protein-1 (MRP-1) and/or other UL138 modulated cell surface proteins. HCMV infected cells may be identified through alterations in the expression MRP-1 and/or other UL138 modulated cell surface proteins, and separated. Mammalian cell populations depleted of HCMV infected cells may be useful, for example in transplants, such as bone marrow transplants.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201108272A GB201108272D0 (en) | 2011-05-17 | 2011-05-17 | Methods relating to HCMV infected cells |
PCT/GB2012/051094 WO2012156733A1 (en) | 2011-05-17 | 2012-05-16 | Detection and depletion of hcmv infected cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201108272A GB201108272D0 (en) | 2011-05-17 | 2011-05-17 | Methods relating to HCMV infected cells |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201108272D0 true GB201108272D0 (en) | 2011-06-29 |
Family
ID=44260678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201108272A Ceased GB201108272D0 (en) | 2011-05-17 | 2011-05-17 | Methods relating to HCMV infected cells |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201108272D0 (en) |
WO (1) | WO2012156733A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2886552A1 (en) * | 2013-12-17 | 2015-06-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Methods for purging isolated organs and cells from latent human cytomegalovirus |
CN107817340A (en) * | 2017-08-01 | 2018-03-20 | 东南大学 | A kind of kit of SERS technology for detection Mdr-p and its application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5783383A (en) * | 1995-05-23 | 1998-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of detecting cytomegalovirus (CMV) |
AU783502B2 (en) * | 1999-11-24 | 2005-11-03 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
WO2002059142A2 (en) * | 2001-01-26 | 2002-08-01 | Epidauros Biotechnologies Ag | Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications |
AU2002242086A1 (en) * | 2001-02-02 | 2002-08-19 | Chemocentryx, Inc. | Chemomagnetic retrieval of cmv and cmv infected cells |
US20100151441A1 (en) * | 2005-09-23 | 2010-06-17 | The Trustees Of Princeton University | Human Cytomegalovirus Latency Promoting Genes, Related Virus Variants and Methods of Use |
-
2011
- 2011-05-17 GB GB201108272A patent/GB201108272D0/en not_active Ceased
-
2012
- 2012-05-16 WO PCT/GB2012/051094 patent/WO2012156733A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012156733A1 (en) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013003681A (en) | Engineered nucleic acids and methods of use thereof. | |
MX2012011779A (en) | 5-position modified pyrimidines and their use. | |
GEP201706605B (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
EP2547346A4 (en) | System for purifying certain cell populations in blood or bone marrow by depleting others | |
MX351659B (en) | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies. | |
IN2014DN07531A (en) | ||
EA201491837A1 (en) | CHEMICAL ANTIGENOUS RECEPTORS AIMED AT ANTIGEN OF B-CELL MATURATION | |
MX2015005675A (en) | Compositions and methods for modulating cell signaling. | |
WO2012019103A8 (en) | System and apparatus for cell treatment | |
MA38632B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
CA2806858C (en) | Reprogramming immortalized b cells | |
AR090973A1 (en) | USEFUL ANTIBODIES FOR CANCER DIAGNOSIS | |
EA201692359A1 (en) | COMPOSITION BASED ON NEW PRRSV STRAIN OR HIS PROTEINS, PRODUCT, THEIR USE, PRRSV VIRUS, ISOLATED NK AND A RECOMBINANT VECTOR OF EXPRESSION FOR OBTAINING THIS VIRUS | |
GB201020995D0 (en) | Biological materials and uses thereof | |
NZ586576A (en) | Improved mammalian expression vectors and uses thereof | |
EA201590247A1 (en) | ANTIBODIES TO SIGLEC-15 | |
GB2513768A (en) | Complexes of cytomegalovirus proteins | |
AR093446A1 (en) | ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE | |
EP4297036A3 (en) | Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex | |
WO2013014294A3 (en) | Improved baculovirus expression systems | |
WO2011021194A3 (en) | Pericyte progenitor cells and methods of generating and using same | |
MX363493B (en) | Cell culture compositions and methods for polypeptide production. | |
EA201491144A1 (en) | METHOD OF FLOCULATION | |
EP3107995A4 (en) | Biophysically sorted osteoprogenitors from culture expanded bone marrow derived mesenchymal stromal cells (mscs) | |
MX2015000754A (en) | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |